Medeiros-Albuquerque
AF, Sampaio-Melo CM, Studart-Soares EC, Rodrigues-Ribeiro T, Roriz-Fonteles CS,
Alves-Pereira KM, Ferreira-Barbosa DA, de-Barros-Silva PG, Gurgel-Costay
FW. Preemptive
analgesia-related gene and protein expression in third molar surgeries under non steroidal anti-inflammatory drug protocols: A
PROSPERO-registered systematic review of clinical studies.
Med Oral Patol Oral Cir Bucal.
2018 Nov 1;23 (6):e723-32.
doi:10.4317/medoral.22576
http://dx.doi.org/doi:10.4317/medoral.22576
|
1. Burian M,
Geisslinger G. COX-dependent mechanisms involved in the antinociceptive
action of NSAIDs at central and peripheral sites. Pharmacol Ther. 2005;107:139-54. |
|
|
|
|
|
2. Lee YS, Kim
H, Wu TX, Wang XM, Dionne RA. Genetically mediated interindividual variation
in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol
Ther. 2006;79:407-18. |
|
|
|
|
|
3. Albuquerque
AFM, Fonteles CRS, do Val DR, Chaves HV, Bezerra MM, Pereira KMA, et al.
Effect of pre-emptive analgesia on clinical parameters and tissue levels of
TNF-a and IL-1b in third molar surgery: a triple-blind, randomized, placebo-
controlled study. Int J Oral Maxillofac Surg. 2017;46:1615-25. |
|
|
|
|
|
4. Lee YS, Kim
H, Brahim JS, Rowan J, Lee G, Dionne RA. Acetaminophen selectively suppresses
peripheral prostaglandin E2 release and increases COX-2 gene expression in a
clinical model of acute inflammation. Pain. 2007;129:279-86. |
|
|
|
|
|
5. Khan AA,
Iadarola M, Yang HT, Dionne RA. Expression of COX-1 and COX-2 in a Clinical
Model of Acute Inflammation. J Pain. 2007;8:349-54. |
|
|
|
|
|
6. Costa FW,
Soares EC, Esses DF, Silva PG, Bezerra TP, Scarparo HC, et al. A split-mouth,
randomized, triple-blind, placebo-controlled study to analyze the pre-emptive
effect of etoricoxib 120 mg on inflammatory events following removal of
unerupted mandibular third molars. Int J Oral Maxillofac Surg. 2015;44:1166-74. |
|
|
|
|
|
7. Costa FW,
Esses DF, de Barros Silva PG, Carvalho FS, S CD, Albuquerque AF, et al. Does
the Preemptive Use of Oral Nonsteroidal Anti-inflammatory Drugs Reduce
Postoperative Pain in Surgical Removal of Third Molars? A Meta-analysis of
Randomized Clinical Trials. Anesth Prog. 2015;62:57-63. |
|
|
|
|
|
8. Moller PL,
Sindet-Pedersen S, Pettersen CT, Juhl GI, Dillenschneider A, Skoglund LA.
Onset of acetaminophen analgesia: comparison of oral intravenous routes after
third molar surgery. Br J Anaesth. 2005;94:642–48. |
|
|
|
|
|
9. Lee Y,
Rodriguez C and Dionne RA. The Role of COX-2 in Acute Pain and the Use of
Selective COX-2 Inhibitors for Acute Pain Relief. Current Pharmaceutical
Design. 2005;11:1737-55. |
|
|
|
|
|
10. Kim K, Brar
P, Jakubowski J, Kaltman S, Lopez E. The use of corticosteroids and
nonsteroidal antiinflammatory medication for the management of pain and
inflammation after third molar surgery: A review of the literature. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod. 2009;107:630-40. |
|
|
|
|
|
11. Huang FM,
Tsai CH, Ding SJ Chang YC. Induction os cyclooxygenase-2 expression in human
pulp cells stimulated by dentin bonding agents. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 2005;100:501-06. |
|
|
|
|
|
12. Khan YS,
Gutirrez-de-Tern H, qvist J. Molecular Mechanisms in the Selectivity of
Nonsteroidal Anti-Inflammatory Drugs. Biochemistry. 2018;57:1236-48. |
|
|
|
|
|
13. Khan AA,
Brahim JS, Rowan JS, Dionne RA. In vivo selectivity of a selective
cyclooxygenase 2 inhibitor in the oral surgery model. Clin Pharmacol Ther.
2002;72:44-9. |
|
|
|
|
|
14. Nguyen DQ,
Eamens AL, Grof CPL. Reference gene identification for reliable normalisation
of quantitative RT-PCR data in Setaria viridis. Plant Methods. 2018;21;14:24. |
|
|
|
|
|
15. Sideri S,
Papageorgiou SN, Eliades T. Are orthodontic systematic reviews registered a
priori in PROSPERO? J Orthod. 2017;7:1-7. |
|
|
|
|
|
16. Uman LS.
Systematic Reviews and Meta-Analyses. J Can Acad Child Adolesc Psychiatry.
2011;20:57-9. |
|
|
|
|
|
17. Moher D,
Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items
for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.
2009;6:e1000097. |
|
|
|
|
|
18. Liberati A,
Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA
statement for reporting systematic reviews and meta-analyses of studies that
evaluate health care interventions: explanation and elaboration. J Clin
Epidemiol 2009;62:1-34. |
|
|
|
|
|
19. Booth A,
Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, Stewart L. The nuts and
bolts of PROSPERO: an international prospective register of systematic
reviews. Syst Rev. 2012;1:2. |
|
|
|
|
|
20. Aromataris
E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing
systematic reviews: methodological development, conduct and reporting of an
umbrella review approach. Int J Evid Based Healthc. 2015;13:132-40. |
|
|
|
|
|
21. Wang XM, Wu
TX, Lee YS, Dionne RA. Rofecoxib regulates the expression of genes related to
the matrix metalloproteinase pathway in humans: implication for the adverse
effects of cyclooxygenase-2 inhibitors. Clin Pharmacol Ther. 2006;79:303-15. |
|
|
|
|
|
22. Wang XM, Wu
TX, Hamza M, Ramsay ES, Wahl SM, Dionne RA. Rofecoxib modulates multiple gene
expression pathways in a clinical model of a acute
inflammatory pain. Pain. 2007;128:136-47. |
|
|
|
|
|
23. Ehrich EW,
Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, et al.
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and
demonstrations of analgesia in the dental pain model. Clin Pharmacol Ther.
1999;65:336-47. |
|
|
|
|
|
24. Cooper SA,
Beaver WT. A model to evaluate mild analgesics in oral surgery outpatients.
Clin Pharmacol Ther. 1976;20:241-50. |
|